Target specific antibody-superantigen conjugates and their preparation
CA 2087164 C · Owner: Akerblom, Eva · Inventors: Lando, Peter; Kalland, Terje; Akerblom, Eva
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell which is recognized by the , antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regimen for cancer autoimmu-, nity, parasitic infestations and fungal viral and bacterial infections. The , specification also describes modes such as the synthesis of the conjugate and pharmaceutical …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 16, 1991 and granted November 26, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 16, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 16, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.